Applications of major histocompatibility complex class I molecules expressed as single chains

Tina Primeau, Nancy B. Myers, Y. Y Lawrence Yu, Lonnie Lybarger, Xiaoli Wang, Steven M. Truscott, Ted H. Hansen, Janet M. Connolly

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Generation of CD8 T-cell responses to pathogens and tumors requires optimal expression of class I major histocompatibility complex/peptide complexes, which, in turn, is dependent on host cellular processing events and subject to interference by pathogens. To create a stable structure that is more immunogenic and resistant to immune evasion pathways, we have engineered class I molecules as single-chain trimers (SCTs), with flexible linkers connecting peptide, β 2m, and heavy chain. Herein we extend our earlier studies with SCTs to the K b ligand derived from vesicular stomatitis virus (VSV) to characterize further SCTs as probes of immune function as well as their potential in immunotherapy. The VSVp-β 2m-K b SCTs were remarkably stable at the cell surface, and immunization with DNA encoding SCTs elicited complex-specific antibody. In addition, SCTs were detected by cytotoxic T-lymphocytes specific for the native molecule, and the covalently bound peptide was highly resistant to displacement by exogenous peptide. SCTs can also prime CD8 T-cells in vivo that recognize the native molecule. Furthermore, SCTs were resistant to downregulation by the immune evasion protein mK3 of γherpesvirus 68. Moreover, owing to their preassembled nature, SCTs should be resistant to other immune evasion proteins that restrict peptide supply. Thus, SCTs possess therapeutic potential both for prophylactic treatment and for the treatment of ongoing infection.

Original languageEnglish (US)
Pages (from-to)109-121
Number of pages13
JournalImmunologic Research
Volume32
Issue number1-3
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Major Histocompatibility Complex
Immune Evasion
Peptides
T-Lymphocytes
Vesicular Stomatitis
C-Peptide
Herpesviridae
Cytotoxic T-Lymphocytes
Immunotherapy
Immunization
Proteins
Therapeutics
Down-Regulation
Ligands
Viruses
Antibodies
DNA
Infection
Neoplasms

Keywords

  • Immune evasion
  • Major histocompatibility complex class I
  • Single-chain trimer
  • Vaccine
  • Vesicular stomatitis virus peptide

ASJC Scopus subject areas

  • Immunology

Cite this

Primeau, T., Myers, N. B., Yu, Y. Y. L., Lybarger, L., Wang, X., Truscott, S. M., ... Connolly, J. M. (2005). Applications of major histocompatibility complex class I molecules expressed as single chains. Immunologic Research, 32(1-3), 109-121. https://doi.org/10.1385/IR:32:1-3:109

Applications of major histocompatibility complex class I molecules expressed as single chains. / Primeau, Tina; Myers, Nancy B.; Yu, Y. Y Lawrence; Lybarger, Lonnie; Wang, Xiaoli; Truscott, Steven M.; Hansen, Ted H.; Connolly, Janet M.

In: Immunologic Research, Vol. 32, No. 1-3, 2005, p. 109-121.

Research output: Contribution to journalArticle

Primeau, T, Myers, NB, Yu, YYL, Lybarger, L, Wang, X, Truscott, SM, Hansen, TH & Connolly, JM 2005, 'Applications of major histocompatibility complex class I molecules expressed as single chains', Immunologic Research, vol. 32, no. 1-3, pp. 109-121. https://doi.org/10.1385/IR:32:1-3:109
Primeau, Tina ; Myers, Nancy B. ; Yu, Y. Y Lawrence ; Lybarger, Lonnie ; Wang, Xiaoli ; Truscott, Steven M. ; Hansen, Ted H. ; Connolly, Janet M. / Applications of major histocompatibility complex class I molecules expressed as single chains. In: Immunologic Research. 2005 ; Vol. 32, No. 1-3. pp. 109-121.
@article{9d5097d17c9b4ac0a8e8f5d239441621,
title = "Applications of major histocompatibility complex class I molecules expressed as single chains",
abstract = "Generation of CD8 T-cell responses to pathogens and tumors requires optimal expression of class I major histocompatibility complex/peptide complexes, which, in turn, is dependent on host cellular processing events and subject to interference by pathogens. To create a stable structure that is more immunogenic and resistant to immune evasion pathways, we have engineered class I molecules as single-chain trimers (SCTs), with flexible linkers connecting peptide, β 2m, and heavy chain. Herein we extend our earlier studies with SCTs to the K b ligand derived from vesicular stomatitis virus (VSV) to characterize further SCTs as probes of immune function as well as their potential in immunotherapy. The VSVp-β 2m-K b SCTs were remarkably stable at the cell surface, and immunization with DNA encoding SCTs elicited complex-specific antibody. In addition, SCTs were detected by cytotoxic T-lymphocytes specific for the native molecule, and the covalently bound peptide was highly resistant to displacement by exogenous peptide. SCTs can also prime CD8 T-cells in vivo that recognize the native molecule. Furthermore, SCTs were resistant to downregulation by the immune evasion protein mK3 of γherpesvirus 68. Moreover, owing to their preassembled nature, SCTs should be resistant to other immune evasion proteins that restrict peptide supply. Thus, SCTs possess therapeutic potential both for prophylactic treatment and for the treatment of ongoing infection.",
keywords = "Immune evasion, Major histocompatibility complex class I, Single-chain trimer, Vaccine, Vesicular stomatitis virus peptide",
author = "Tina Primeau and Myers, {Nancy B.} and Yu, {Y. Y Lawrence} and Lonnie Lybarger and Xiaoli Wang and Truscott, {Steven M.} and Hansen, {Ted H.} and Connolly, {Janet M.}",
year = "2005",
doi = "10.1385/IR:32:1-3:109",
language = "English (US)",
volume = "32",
pages = "109--121",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - Applications of major histocompatibility complex class I molecules expressed as single chains

AU - Primeau, Tina

AU - Myers, Nancy B.

AU - Yu, Y. Y Lawrence

AU - Lybarger, Lonnie

AU - Wang, Xiaoli

AU - Truscott, Steven M.

AU - Hansen, Ted H.

AU - Connolly, Janet M.

PY - 2005

Y1 - 2005

N2 - Generation of CD8 T-cell responses to pathogens and tumors requires optimal expression of class I major histocompatibility complex/peptide complexes, which, in turn, is dependent on host cellular processing events and subject to interference by pathogens. To create a stable structure that is more immunogenic and resistant to immune evasion pathways, we have engineered class I molecules as single-chain trimers (SCTs), with flexible linkers connecting peptide, β 2m, and heavy chain. Herein we extend our earlier studies with SCTs to the K b ligand derived from vesicular stomatitis virus (VSV) to characterize further SCTs as probes of immune function as well as their potential in immunotherapy. The VSVp-β 2m-K b SCTs were remarkably stable at the cell surface, and immunization with DNA encoding SCTs elicited complex-specific antibody. In addition, SCTs were detected by cytotoxic T-lymphocytes specific for the native molecule, and the covalently bound peptide was highly resistant to displacement by exogenous peptide. SCTs can also prime CD8 T-cells in vivo that recognize the native molecule. Furthermore, SCTs were resistant to downregulation by the immune evasion protein mK3 of γherpesvirus 68. Moreover, owing to their preassembled nature, SCTs should be resistant to other immune evasion proteins that restrict peptide supply. Thus, SCTs possess therapeutic potential both for prophylactic treatment and for the treatment of ongoing infection.

AB - Generation of CD8 T-cell responses to pathogens and tumors requires optimal expression of class I major histocompatibility complex/peptide complexes, which, in turn, is dependent on host cellular processing events and subject to interference by pathogens. To create a stable structure that is more immunogenic and resistant to immune evasion pathways, we have engineered class I molecules as single-chain trimers (SCTs), with flexible linkers connecting peptide, β 2m, and heavy chain. Herein we extend our earlier studies with SCTs to the K b ligand derived from vesicular stomatitis virus (VSV) to characterize further SCTs as probes of immune function as well as their potential in immunotherapy. The VSVp-β 2m-K b SCTs were remarkably stable at the cell surface, and immunization with DNA encoding SCTs elicited complex-specific antibody. In addition, SCTs were detected by cytotoxic T-lymphocytes specific for the native molecule, and the covalently bound peptide was highly resistant to displacement by exogenous peptide. SCTs can also prime CD8 T-cells in vivo that recognize the native molecule. Furthermore, SCTs were resistant to downregulation by the immune evasion protein mK3 of γherpesvirus 68. Moreover, owing to their preassembled nature, SCTs should be resistant to other immune evasion proteins that restrict peptide supply. Thus, SCTs possess therapeutic potential both for prophylactic treatment and for the treatment of ongoing infection.

KW - Immune evasion

KW - Major histocompatibility complex class I

KW - Single-chain trimer

KW - Vaccine

KW - Vesicular stomatitis virus peptide

UR - http://www.scopus.com/inward/record.url?scp=23844447258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844447258&partnerID=8YFLogxK

U2 - 10.1385/IR:32:1-3:109

DO - 10.1385/IR:32:1-3:109

M3 - Article

C2 - 16106063

AN - SCOPUS:23844447258

VL - 32

SP - 109

EP - 121

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -